Categories: News

CordenPharma enters into a technology alliance agreement with Nanos of South Korea 

SEOUL, South Korea, March 29, 2021 (GLOBE NEWSWIRE) — CordenPharma of Germany entered into a technology alliance agreement with Nanos (151910 KOSDAQ) of South Korea relating to the production of Peptides.

Nanos is a top supplier of camera modules for Samsung Electronics’ mobile phone business.  

Due to a relocation of Samsung Electronics’ mobile business to Vietnam, Nanos’ manufacturing factory in Hwasung, Korea, remains out of production. 

Through in-licensing or a large-scale direct investment, Nanos plans to transform and utilize the existing production facility to launch high value products, such as Peptides, a potential agent for cancer immunotherapy drugs.  

Nanos’ partnership with CordenPharma, one of the leading global development and manufacturing organizations (CDMO), represents Nanos’ strategic intention to establish long-term production and sale of therapeutic drugs involving Peptides, which are currently in Phase 2 clinical trials.

Press Contact: Kenny Bang
E-mail : supergto314151@gmail.com

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

50 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

51 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

4 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

5 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

19 hours ago